What is hemophilia?
Hemophilia is a genetic disorder that impairs the body’s ability to make blood clots, a process needed to stop bleeding. This condition can lead to prolonged bleeding or spontaneous bleeding.
How prevalent is hemophilia in India?
India has one of the largest populations of persons with hemophilia, with an estimated 136,000 individuals living with the condition, although only around 21,000 are registered for treatment.
What are the new national guidelines for hemophilia treatment in India?
The new guidelines include the use of innovative products like Emicizumab, now available in India, which can prevent bleeding in people with hemophilia A, even those who have developed inhibitors to standard treatments.
What is the aim of these guidelines?
The aim is to provide cost-effective treatment, reduce mortality and morbidity associated with hemophilia, and improve the overall quality of life for patients.
How do these guidelines affect the standard of care?
The guidelines advocate for comprehensive care, including the significance of timely diagnosis, physiotherapy, and multidisciplinary care to manage the condition effectively.
What challenges do patients with hemophilia face in India?
Many patients may not receive optimal treatment due to a lack of awareness, insufficient healthcare infrastructure, or the high cost of treatment. There is also a challenge with the availability of modern treatment options across all healthcare facilities.
